MORPHOSYS AG |
Market Closed -
Other stock markets
|
Pre-market 01:32:01 | |||
| 67.3 EUR | -0.44% |
|
67.62 | +0.48% |
| Sales 2024 * | 123M 132M 180M | Sales 2025 * | 325M 351M 478M | Capitalization | 2.55B 2.75B 3.74B |
|---|---|---|---|---|---|
| Net income 2024 * | -430M -464M -632M | Net income 2025 * | -116M -125M -171M | EV / Sales 2024 * | 21.5 x |
| Net Debt 2024 * | 89.28M 96.31M 131M | Net cash position 2025 * | 94.69M 102M 139M | EV / Sales 2025 * | 7.54 x |
| P/E ratio 2024 * |
-5.99
x | P/E ratio 2025 * |
-32.5
x | Employees | 464 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 5.65% |
More Fundamentals
* Assessed data
More news
Latest transcript on MorphoSys AG
More press releases
More news
| 1 day | +0.48% | ||
| 1 week | -0.30% | ||
| Current month | -0.44% | ||
| 1 month | -1.46% | ||
| 3 months | +1.13% | ||
| 6 months | +103.63% | ||
| Current year | +92.84% |
1 week
67.15
67.75
1 month
64.4068.05
Current year
30.1170.15
1 year
14.9370.15
3 years
11.8070.15
5 years
11.80151.00
10 years
11.80151.00
| Managers | Title | Age | Since |
|---|---|---|---|
Luisa Ciccarelli
CTO | Chief Tech/Sci/R&D Officer | - | 21-07-31 |
Tim Demuth
CTO | Chief Tech/Sci/R&D Officer | 50 | 22-09-30 |
Julia Neugebauer
IRC | Investor Relations Contact | - | 06-08-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Sharon Curran
BRD | Director/Board Member | 56 | 19-05-21 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-07-03 | 67.3 | -0.44% | 30 |
| 24-07-02 | 67.6 | 0.00% | 41 |
| 24-07-01 | 67.6 | 0.00% | 3 |
| 24-06-28 | 67.6 | +0.60% | 30 |
| 24-06-27 | 67.2 | -0.44% | 100 |
Delayed Quote Deutsche Boerse AG, July 03, 2024 at 09:59 am
More quotes
MorphoSys AG is a global commercial-stage biopharmaceutical company based in Germany. The Company discovers, develops, and delivers cancer medicines to patients. It markets its proprietary medicine Monjuvi (tafasitamab-cxix) in the United States, a cancer immunotherapy treatment, used to treat patients in combination with lenalidomide with second and later lines of diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplant. Tafasitamab is also being evaluated in a global clinical trial as a first line therapy for DLBCL. Two additional product candidates are in late and mid-stage clinical development in oncology indications: pelabresib, a small-molecule BET inhibitor, is studied as a treatment for myelofibrosis, a type of bone marrow cancer for which treatment options are limited; and CPI-0209, a second generation EZH2 inhibitor, is studied for treating hematological and solid tumors.
Calendar
2024-08-06
- Q2 2024 Earnings Call
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
HOLD
Number of Analysts
8
Last Close Price
67.6
EUR
Average target price
58.71
EUR
Spread / Average Target
-13.14%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +16.59% | 44.44B | |
| -10.62% | 37.68B | |
| +40.49% | 39.84B | |
| +29.92% | 31.46B | |
| -9.78% | 27.02B | |
| +12.34% | 26.29B | |
| +41.53% | 13.8B | |
| +31.49% | 12.46B | |
| -7.40% | 11.26B |
- Stock Market
- Equities
- MOR Stock
- MOR Stock
